FIG. 10.

Systemic injection of 2 mg/kg RGFP966 every 3 days results in protection against BRN3A expression loss at 2 weeks post ONC and total cell loss at 4 weeks post ONC. Mice were either injected IP with 30% HPβCD 0.1 M acetate (pH 5.4) vehicle, 2, or 10 mg/kg RGFP966 every 3 days following ONC. Fourteen and 28 days after ONC, retinas were harvested, whole mounted, and stained for BRN3A and DAPI for counting cells. (A) At 2 weeks post ONC, experimental retinas from eyes of mice IP injected with vehicle contained significantly fewer BRN3A-labeled cells than in 2 or 10 mg/kg RGFP966-treated mice (P = 0.002 and P < 0.0001, respectively). IP injection of 10 mg/kg provided significantly more protection against loss of BRN3A expression than 2 mg/kg treated mice (P < 0.0001). (B) By 4 weeks post ONC, however, IP injection of RGFP966 at either concentration failed to prevent the loss of BRN3A. (C) Total cell counts based on DAPI labeling indicated a significant attenuation of cell loss in 2 mg/kg treated eyes over eyes in mice IP injected with vehicle or 10 mg/kg (P = 0.002 and P < 0.0001, respectively). Greater cell loss relative to vehicle-treated mice was detected in 10 mg/kg treated animals (P = 0.001).